Table 1.
Distribution of 682 cases of COVID-19 (reverse-transcriptase–PCR SARS-CoV-2 positive) aged < 20 years in Pernambuco, Brazil, from March 12 to June 19, 2020, according to age, gender, symptoms/signs, comorbidities, pregnancy–puerperal cycle, and fatality
| Age-group | < 20 years | < 30 days | 1–11 months | 1–4 years | 5–9 years | 10–14 years | 15–19 years |
|---|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Patients | 682 | 61 (8.9) | 84 (12.3) | 108 (15.8) | 89 (13.1) | 104 (15.3) | 236 (34.6) |
| Gender | |||||||
| Male | 322 (47.2) | 31 (50.8) | 45 (53.6) | 52 (48.2) | 40 (44.9) | 47 (45.2) | 107 (45.3) |
| Female | 360 (52.8) | 30 (49.2) | 39 (46.4) | 56 (51.8) | 49 (55.1) | 57 (54.8) | 129 (54.7) |
| Symptoms/signs* | |||||||
| Asymptomatic | 6 (0.9) | 1 (1.6) | 1 (1.2) | 0 | 2 (2.3) | 2 (1.9) | – |
| Fever | 439 (64.4) | 27 (44.3) | 51 (60.7) | 79 (73.2) | 60 (67.4) | 65 (62.5) | 157 (66.5) |
| Adynamia | 13 (1.9) | 1 (1.6) | 1 (1.2) | 2 (1.9) | 2 (2.3) | 1 (1.0) | 6 (2.5) |
| Body pain/myalgia | 33 (4.8) | 1 (1.6) | 4 (4.8) | 3 (2.8) | 4 (4.5) | 8 (7.7) | 13 (5.5) |
| Headache | 73 (10.7) | – | 3 (3.6) | 6 (5.7) | 8 (9.0) | 13 (12.5) | 43 (18.2) |
| Runny nose | 58 (8.5) | 3 (4.9) | 18 (21.4) | 10 (9.3) | 6 (6.7) | 5 (4.8) | 16 (6.8) |
| Nasal obstruction | 47 (6.9) | 2 (3.3) | 15 (17.9) | 10 (9.3) | 3 (3.4) | 5 (4.8) | 12 (5.1) |
| Sore throat | 159 (23.3) | 5 (8.2) | 6 (7.1) | 11 (10.2) | 23 (25.8) | 33 (31.7) | 81 (34.3) |
| Cough | 357 (52.4) | 20 (32.8) | 44 (52.4) | 61 (56.5) | 38 (42.7) | 60 (57.7) | 134 (56.8) |
| Respiratory discomfort | 220 (32.3) | 33 (54.1) | 44 (52.4) | 38 (35.2) | 24 (27.0) | 23 (22.1) | 58 (24.6) |
| O2 saturation < 95% | 103 (15.1) | 13 (21.3) | 20 (23.8) | 24 (22.2) | 12 (13.5) | 10 (9.6) | 24 (10.2) |
| Diarrhea | 76 (11.4) | 5 (8.2) | 15 (17.9) | 17 (15.7) | 15 (10.6) | 11 (10.6) | 13 (5.5) |
| Nausea, vomiting | 50 (7.3) | – | 8 (9.5) | 11 (10.2) | 11 (12.4) | 8 (7.7) | 12 (5.1) |
| Abdominal pain | 7 (1.0) | – | – | 3 (2.8) | 3 (3.4) | 1 (1.0) | – |
| Skin manifestations | 4 (0.6) | – | – | 1 (0.9) | 1 (1.2) | 1 (1.0) | 1 (0.4) |
| Smell alteration | 36 (5.3) | – | 1 (1.2) | 3 (2.8) | 1 (1.1) | 4 (3.9) | 27 (11.4) |
| Taste alteration | 33 (4.8) | – | 1 (1.2) | 3 (2.8) | 1 (1.1) | 3 (2.9) | 25 (10.6) |
| Other reported symptoms* | 15 (2.2) | – | – | – | – | – | – |
| No information | 39 (5.7) | – | – | – | – | – | – |
| Comorbidities† | |||||||
| Leukemia | 19 (2.8) | – | – | – | – | – | – |
| Solid tumors | 15 (2.2) | – | – | – | – | – | – |
| Chronic lung disease | 10 (1.5) | – | – | – | – | – | – |
| Asthma | 5 (0.7) | – | – | – | – | – | – |
| Neurological disease | 9 (1.3) | – | – | – | – | – | – |
| Autoimmune disease/immunosuppression | 3 (0.4) | – | – | – | – | – | – |
| Hematological disease | 3 (0.4) | – | – | – | – | – | – |
| History of prematurity ± bronchodysplasia | 4 (0.6) | – | – | – | – | – | – |
| Other | 10 (1.5) | – | – | – | – | – | – |
| Pregnancy/puerperium | 17 (2.5) | – | – | – | – | 1 (1.0) | 16 (6.8) |
| Hospitalization | |||||||
| Yes | 315 (46.2) | 49 (80.3) | 62 (73.8) | 67 (62.0) | 33 (37.1) | 38 (36.5) | 66 (28.0) |
| No | 97 (14.2) | 5 (8.2) | 8 (9.5) | 15 (13.9) | 13 (14.6) | 17 (16.4) | 39 (16.5) |
| No information | 270 (39.6) | 7 (11.5) | 14 (16.7) | 26 (24.7) | 43 (48.3) | 49 (47.1) | 131 (55.5) |
| Death (fatality rate) | 38 (5.6) | 7 (11.5) | 8 (9.5) | 6 (5.6) | 5 (5.6) | 2 (1.92) | 10 (4.24) |
Data were provided by the Secretariat of Planning and Management of Pernambuco (SEPLAG PE).
Other symptoms = malaise, drowsiness, dizziness, anorexia, tachycardia, otalgia, ocular pain, ocular secretion.
Seventy patients presented with one comorbidity and four with two comorbidities; Other comorbidities: two children with chromosomal abnormalities, one with congenital heart disease and hydrocephalus, two with microcephaly, one with lactose intolerance, one with hypertension, one with mental disorder, one with diabetes mellitus, one with pneumonia and pleural effusion, and one with tuberculosis.